3
Announcements
Trials
Browse
Landscape
Status
Approved for marketing
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
13
Observational
5
Expanded_access
1
Sponsor
Cancer Type
CNS
1
Conditions
Glioblastoma
15
Neuroblastoma
13
Glioma
11
Pheochromocytoma
7
Neoplasms
6
Recurrence
5
Paraganglioma
5
Pancreatic Neoplasms
3
Melanoma
3
Head and Neck Neoplasms
3
Brain Neoplasms
3
Stomach Neoplasms
2
Ovarian Neoplasms
2
Oligodendroglioma
2
Neurofibroma, Plexiform
2
Neuroectodermal Tumors, Primitive
2
Medulloblastoma
2
Diffuse Intrinsic Pontine Glioma
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Astrocytoma
2
Wilms Tumor
1
Urinary Bladder Neoplasms
1
Typical Teratoid Rhabdoid Tumor
1
Thyroid cancer, medullary
1
Thyroid Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Interventions
vorasidenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Expanded_access
×
Neuroectodermal Tumors
×
CNS
×
Clear all
NCT05592743
2024-11-05
Vorasidenib Expanded Access Program
Servier
Approved for marketing